Loading...
|
Please use this identifier to cite or link to this item:
https://ir.cnu.edu.tw/handle/310902800/27022
|
| Title: | Serum Vascular Adhesion Protein-1 Predicts 10-Year Cardiovascular and Cancer Mortality in Individuals With Type 2 Diabetes |
| Authors: | Li, Hung-Yuan
Jiang, Yi-Der
Chang, Tien-Jyun
Wei, Jung-Nan
Lin, Mao-Shin
Lin, Cheng-Hsin
Chiang, Fu-Tien
Shih, Shyang-Rong
Hung, Chi Sheng
Hua, Cyue-Huei
David, J.Smith
Vanio, Jani
Chuang, Lee-Ming |
| Contributors: | 職業安全衛生系 |
| Keywords: | Sensitive Amine Oxidase
Hepatocellular-Carcinoma
Colorectal-Cancer
Leukocyte Binding
Tumor Endothelium
P-Selectin
Disease
Risk
Overexpression
Adipocytes |
| Date: | 2011-03 |
| Issue Date: | 2013-10-23 11:55:48 (UTC+8) |
| Publisher: | Amer Diabetes Assoc |
| Abstract: | OBJECTIVE Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 correlates positively with both acute hyperglycemia and diabetes. We conducted a cohort study to evaluate whether serum VAP-1 predicts 10-year survival in type 2 diabetic patients.
RESEARCH DESIGN AND METHODS Between July 1996 and June 2003, we enrolled 661 type 2 diabetic subjects at National Taiwan University Hospital. Serum VAP-1 in the samples obtained at enrollment was measured by time-resolved immunofluorometric assay. The vital status of all subjects was ascertained by linking their data with computerized death certificates in Taiwan.
RESULTS The medium follow-up period was 10.4 years. Subjects with serum VAP-1 in the highest tertile had a hazard ratio (HR) of 2.19 (95% CI 1.17–4.11) for all-cause mortality adjusted for age, sex, smoking, history of cardiovascular disease, obesity, hypertension, hemoglobin A1c, diabetes duration, total cholesterol, use of statins, abnormal ankle-brachial index, estimated glomerular filtration rate (eGFR), and proteinuria. The adjusted HRs for logarithmically transformed serum VAP-1 were 5.83 (95% CI 1.17–28.97) for cardiovascular mortality, 6.32 (95% CI 1.25–32.00) for mortality from cardiovascular and diabetic causes, and 17.24 (95% CI 4.57–65.07) for cancer mortality. There were four variables, including age, serum VAP-1, proteinuria, and eGFR, which could enhance mortality prediction significantly.
CONCLUSIONS Serum VAP-1 can predict 10-year all-cause mortality, cardiovascular mortality, and cancer mortality independently in type 2 diabetic subjects. Serum VAP-1 is a novel biomarker that improves risk prediction over and above established risk factors |
| Relation: | Diabetes , 60(3), pp.993-999 |
| Appears in Collections: | [Dept. of Occupational Safety] Periodical Articles
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| index.html | | 0Kb | HTML | 1995 | View/Open |
|
All items in CNU IR are protected by copyright, with all rights reserved.
|
